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Abstract 1 
Purpose:  Methicillin-resistant Staphylococcus aureus (MRSA) is an important cause of 2 
pneumonia in ventilated patients. Our objective was to evaluate the GeneXpert 3 
MRSA/SA SSTI Assay (Xpert MRSA/SA) (Cepheid, Sunnyvale, CA) for use in lower 4 
respiratory tract (LRT) specimens for rapid MRSA detection and to determine the 5 
potentially saved antibiotic-days if a culture-based identification method was replaced 6 
by this assay.  7 
Methods:  Remnant LRT samples from ventilated patients submitted to the 8 
microbiology laboratory for routine culture were tested using conventional culture and 9 
Xpert MRSA/SA.  10 
Results:  One hundred (100) of 310 LRT specimens met inclusion criteria. Ten (10) 11 
samples were positive for MRSA by Xpert MRSA/SA, while 6 were positive by routine 12 
culture methods. Xpert MRSA/SA correctly identified 5/6 positive and 89/94 negative 13 
MRSA specimens for a sensitivity of 83.3%, specificity of 94.7%, positive predictive 14 
value of 45.6% and a negative predictive value of 98.9%. The assay also correctly 15 
detected 3/3 positive and 90/97 negative MSSA specimens for a sensitivity of 100%, 16 
specificity of 92.8%, positive predictive value of 30% and a negative predictive value of 17 
100%. A total of 748 vancomycin and 305 linezolid antibiotic days were associated with 18 
the enrolled specimens. Vancomycin and linezolid utilization could decrease by 68.4% 19 
and 83%, respectively, if discontinued 1 day after negative PCR results.  20 
Conclusions: The Xpert MRSA/SA SSTI rapid MRSA PCR assay performed well in 21 
respiratory samples from ventilated patients with suspected pneumonia and has the 22 
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potential to facilitate stewardship efforts such as reducing empiric vancomycin and 23 
linezolid therapy. 24 
Keywords: MRSA, PCR, antimicrobial stewardship, ventilator-associated pneumonia, 25 
Xpert MRSA, Staphylococcus aureus 26 
 27 
Introduction 28 
Methicillin-resistant Staphylococcus aureus (MRSA) is an important cause of ventilator-29 
associated pneumonia (VAP) in the U.S. For patients with suspected VAP, treatment 30 
guidelines suggest empirical therapy to cover MRSA in addition to other potential 31 
pathogens [1]. Using conventional microbiologic methods, however, 48 h or more may 32 
elapse before MRSA can be reliably excluded from a lower respiratory tract (LRT) 33 
specimen, with tracheal aspirate (TA), bronchial washing (BW), or bronchoalveolar 34 
lavage (BAL) being the most frequently obtained specimen types. Thus, clinicians are 35 
faced with a long interval of diagnostic uncertainty, obligating prolonged use of broad-36 
spectrum empiric antibiotic therapy.   37 
The Xpert MRSA/SA SSTI (Cepheid, Sunnyvale, CA) assay is a polymerase 38 
chain reaction (PCR)-based assay, which is FDA cleared for detection of MRSA and 39 
methicillin-susceptible S. aureus (MSSA) in specimens collected from skin and soft 40 
tissue infections. The assay provides a result in approximately 1 h. To detect S. aureus, 41 
the assay relies on the detection of spa, the gene for staphylococcal protein A. To infer 42 
resistance to methicillin and identify the organism as MRSA, it must also detect the 43 
methicillin-resistance gene (mecA) and the junction between the staphylococcal 44 
cassette chromosome that harbors mecA (SCCmec) and the S. aureus chromosome. 45 
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The assay has been adapted for off-label use to detect MRSA in suspected ventilator-46 
associated pneumonia [2,3] and osteoarticular infections [4].  47 
Preliminary data in our institution demonstrate that approximately 20% of patients 48 
with cultures from LRT secretions obtained from Medical and Surgical Intensive Care 49 
Units (ICUs) were positive for S. aureus, with 9% determined to be methicillin-resistant.  50 
The Xpert MRSA/SA SSTI assay could be beneficial to reduce the interval of diagnostic 51 
uncertainty by identifying or ruling out MRSA in patients with suspected VAP and 52 
guiding antimicrobial therapy in a more timely fashion compared to conventional culture. 53 
The objectives of this study were two-fold: 1) to evaluate the analytical performance 54 
characteristics of the MRSA/SA SSTI assay for rapid detection of MRSA in LRT 55 
specimens and 2) to evaluate its potential role in antimicrobial stewardship efforts for 56 
managing suspected VAP, specifically concerning anti-MRSA agents. 57 
 58 
Materials and Methods 59 
Setting.  Frozen and fresh LRT specimens collected at Barnes-Jewish Hospital, a 1,250 60 
bed, tertiary care academic medical center, between 2012 and 2014 were included. The 61 
study was approved by the Washington University School of Medicine Institutional 62 
Review Board. All specimens included in the study were de-identified by an individual 63 
not otherwise associated with the study (i.e., the Honest Broker).    64 
 65 
Standard-of-Care LRT Culture.  BAL, BW and TA cultures were plated to 5% sheep’s 66 
blood, chocolate and MacConkey agar (Remel, Lenexa, KS), using a 1 µl calibrated 67 
loop, and incubated at 35°C in an environment with 5% CO2. Thresholds for workup of 68 
5 
 
BAL, BW and TA specimens were ≥ 103 CFU/mL, ≥ 5x103 CFU/mL, and ≥ 105 CFU/mL, 69 
respectively. Cultures were discarded if no growth was observed following 48 h of 70 
incubation. In S. aureus, methicillin resistance was confirmed using Kirby-Bauer disk 71 
diffusion in accordance with Clinical and Laboratory Standards Institute (CLSI) 72 
guidelines [5,6]. This standard-of-care LRT culture was used as the gold standard for 73 
comparison when calculating the analytical performance characteristics of the Xpert 74 
MRSA/SA.    75 
 76 
Limit of detection (LOD) and reproducibility studies. LOD studies were performed 77 
using cultured isolates of Staphylococcus epidermidis (clinical isolate), S. aureus ATCC 78 
29213 (MSSA), MRSA SCCmec type II, and MRSA SCCmec type IV (clinical isolates). 79 
Isolates were resuspended in 0.9% saline to a 0.5 McFarland and subsequently diluted 80 
to final concentrations of 105, 104, 103 and 102 CFU/mL. In addition, a negative saline 81 
control was analyzed. Subsequently, LOD studies were repeated in the matrix of 82 
pooled, S. aureus-negative, BAL fluid.  Replicate testing, using 104 CFU/mL of the same 83 
group of organisms in BAL fluid, was performed over three consecutive days. 84 
 85 
Retrospective samples. Study procedures were approved by the Washington 86 
University School of Medicine Institutional Review Board.  Thirty (30) frozen banked 87 
LRT specimens (including 13 TAs and 17 BALs), obtained during routine diagnostic 88 
work-up prior to this study, were tested using the Xpert MRSA/SA SSTI assay, and the 89 
results were compared to the standard-of-care LRT culture result performed in the 90 
clinical microbiology laboratory. A flocked swab (Copan, Murrieta, CA) was placed into 91 
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the specimen and subsequently inserted into the Xpert elution buffer vial. Next, the 92 
swab was broken, and the vial was closed and vortexed for 10 sec. A sterile pipette was 93 
used to transfer the contents of the elution vial to the “S” chamber of the Xpert 94 
MRSA/SA cartridge, and the cartridge was loaded onto the GeneXpert Dx instrument. 95 
Testing was otherwise performed and results interpreted according to the 96 
manufacturer’s protocol.   97 
 98 
Prospective samples. Specimens submitted to the microbiology laboratory for routine 99 
bacterial culture during the study period (November 2013 to March 2014) were 100 
screened by an Honest Broker for study eligibility in the prospective part of the study. 101 
The following 6 items were inclusion criteria: 1) subject ≥18 years of age, 2) patient 102 
admitted to the ICU, 3) patient on a ventilator at the time of sample collection, 4) ≥1 ml 103 
of remnant TA, BAL, or BW specimen available, 5) specimen tested by GeneXpert 104 
within 6 h of collection, and 6) presence of at least one of the following clinical criteria: 105 
a) active or recently discontinued use of broad-spectrum antibiotics (vancomycin, 106 
linezolid, cefepime or meropenem), b) temperature >38.3°C (within previous 72 h), c) 107 
white blood cell or leukocyte count ≥10,000/µl or ≤4,000/µl (within  72 h of specimen 108 
collection), d) purulent specimen (>25 polymorphonuclear cells/high power field) or e) 109 
recent intubation (within 72 h of specimen collection). Patients with a previous positive 110 
result from the Xpert MRSA/SA assay were excluded. 111 
Specimens were screened for eligibility three times per day on weekdays by the 112 
Honest Broker. Three hundred ten (310) LRT specimens were screened, and 100 113 
specimens met the study inclusion criteria and were tested using the Xpert MRSA/SA.  114 
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In addition to the standard-of-care culture, if a specimen was positive for MSSA 115 
or MRSA by the Xpert MRSA/SA, 100 µl and 500 µl aliquots were inoculated to blood 116 
agar (BD Diagnostics, Franklin Lakes, NJ), in addition to the standard-of-care culture, to 117 
attempt to isolate the organism. Isolates recovered using the larger aliquots were not 118 
included in sensitivity, specificity, positive predictive value (PPV) and negative predictive 119 
value (NPV) calculations.  120 
 121 
Molecular Typing. SCCmec characterization was performed on S. aureus isolates 122 
using a previously described multiplex PCR assay that detects and differentiates 123 
SCCmec types I-V [7].  Strain typing of S. aureus isolates was performed by repetitive-124 
sequence-based PCR (rep-PCR), using the Diversilab Bacterial Barcodes system 125 
(bioMérieux, Durham, NC) as previously described [8]. Isolates with a similarity index of 126 
≥95% were considered to represent the same strain. 127 
 128 
Detection of high-level mupirocin resistance and chlorhexidine resistance. 129 
Phenotypic high-level mupirocin resistance was detected using a 200 µg mupirocin disk 130 
(Oxoid, Hampshire, United Kingdom) in accordance with CLSI guidelines [5]. In addition 131 
to phenotypic mupirocin resistance testing, a multiplex PCR for detection of mupA 132 
(mupirocin resistance) and qacA/B (chlorhexidine tolerance) was performed as 133 
previously described [8,9].  134 
 135 
Antimicrobial stewardship applicability. Clinical data on subjects whose specimens 136 
met eligibility criteria were obtained from Washington University’s medical informatics 137 
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clinical data repository, including microbiological culture results (for the LRT specimen 138 
tested in the study, in addition to any other positive culture results) as well as 139 
antimicrobials utilized. “Total antibiotic days” (all consecutive days that antibiotics were 140 
administered starting 48 hours prior to the study specimen collection date, until 141 
discontinued), were calculated for vancomycin and linezolid. Other antibiotics with 142 
activity against MRSA were not included. The number of antibiotic days that could have 143 
potentially been avoided was calculated using the “earliest date when antibiotics could 144 
be discontinued.” This was calculated as the calendar day after a negative MRSA PCR, 145 
given that no other clinical cultures were positive for MRSA. The potential reduction of 146 
antibiotic use (i.e., the number of antibiotic-days saved) was calculated by subtracting 147 
this number from the total antibiotic days. 148 
 149 
Results 150 
Limit of Detection Studies. The LOD in saline was 103 CFU/ml for MSSA and MRSA 151 
SCCmec type IV. For MRSA SCCmec type II, the LOD was 104 CFU/ml. In BAL fluid, 152 
the LOD was 103 CFU/ml for MSSA and MRSA SCCmec type II, while it was104 CFU/ml 153 
for MRSA SCCmec type IV.  154 
 155 
Retrospective validation samples. The Xpert MRSA/SA SSTI assay correctly 156 
detected MRSA in 9 of 9 specimens positive by routine culture and did not detect MRSA 157 
in 21 of 21 specimens negative by routine culture, resulting in a sensitivity of 100% 158 
(95% CI: 62.9-100%), specificity of 100% (95% CI: 80.8-100%), PPV of 100% (95% CI: 159 
62.9-100%) and NPV of 100% (95% CI: 80.8-100%). In addition, MSSA was correctly 160 
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detected in 4 of 6 specimens positive by routine culture and was not detected in 24 of 161 
24 specimens negative by routine culture, resulting in a sensitivity of 66.7% (95% CI: 162 
24.1-94.0%), specificity of 100% (95% CI: 82.8-100%),  PPV of 100% (95% CI: 39.6-163 
100%) and NPV of 92.3% (95% CI: 73.4-98.7%). Four (4) isolates of MSSA and 7 164 
isolates of MRSA were recovered from the subset of frozen specimens saved for 165 
molecular analysis.  166 
 167 
Prospective samples. Of the 100 prospective specimens, which included BALs, TAs, 168 
and BWs, Xpert MRSA/SA detected MRSA in 5 of 6 specimens positive by standard-of 169 
care culture resulting in a sensitivity of 83.3% (95% CI: 36.5-99.1%). The false negative 170 
was a BAL specimen. Xpert MRSA/SA detected MRSA in an additional 5 specimens, 4 171 
BALs and 1 BW, where MRSA was not recovered by routine culture, resulting in a 172 
specificity of 94.7% (95% CI: 87.5-98.0%), a positive predictive value (PPV) of 50% 173 
(95% CI: 20.1-79.9%) and a negative predictive value (NPV) of 98.9% (95% CI: 93.1-174 
99.9%) (Table 1).   Of note, in higher volume cultures (500 µL, was inoculated to 5% 175 
sheep’s blood agar) MRSA was recovered in 3 of the 5 specimens that were negative 176 
by routine culture but positive by PCR. Mean cycle threshold (Ct) values were as 177 
follows: spa 26.41 (range 16.5–35.5), mecA 26.58 (range 17.6–32.5) and scc 27.94 178 
(range 19.2–34.6) (Table 2). 179 
 180 
 The Xpert MRSA/SA assay detected MSSA in 3 of 3 specimens positive by 181 
routine culture, resulting in a sensitivity of 100% (95% CI: 31.0-100%). In addition, 182 
MSSA was detected in an additional 7 specimens, 5 BALs and 2 TAs, which were 183 
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negative by routine culture, for a specificity of 92.8% (95% CI: 85.2-96.8%).  The PPV 184 
and NPV for MRSA were 30.0% (95% CI: 8.1-64.6%) and 100% (95% CI: 94.9-100%), 185 
respectively. In higher volume cultures (500 µl inoculated to 5% sheep’s blood agar), 186 
MSSA was recovered in 2 additional specimens. The average spa cycle threshold was 187 
29.32 (range 16.5 – 35.5) (Table 2). The spa cycle threshold for the 2 specimens in 188 
which MSSA was only recovered when plating 500 µl were 26.2 and 29.9. 189 
 Of the 100 prospective specimens, 36 were visibly bloody, and 13 specimens 190 
contained visible mucus; these specimens produced an Xpert MRSA/SA result on the 191 
first attempt with the exception of one viscous specimen, which resulted in a pressure 192 
error. The assay was repeated on the same specimen, and a valid result was obtained. 193 
Of the 51 non-bloody, non-viscous specimens, 3 specimens did not give a result on the 194 
first attempt. Two of the specimens gave an error message on the first run, while a third 195 
specimen gave an invalid result. The invalid specimen and one of specimens with an 196 
error message yielded a valid result upon repeating the assay. One specimen, that gave 197 
an error message on the first attempt, gave an invalid result on the second attempt. The 198 
specimen had to be diluted 1:10 with sterile saline before a valid result was obtained. 199 
Overall, the assay had to be repeated 4% of the time.  200 
 201 
Characterization of isolates. A total of 15 MRSA and 9 MSSA isolates recovered from 202 
retrospective and prospective specimens were further characterized by SCCmec typing, 203 
high-level mupirocin resistance, chlorhexidine resistance, and molecular typing. Of the 204 
15 MRSA isolates recovered, 12 isolates were SCCmec type II, and 3 isolates were 205 
SCCmec type IV. All 9 MSSA isolates were negative by SCCmec typing. Analysis of the 206 
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24 isolates by rep-PCR demonstrated heterogeneity of strains recovered. In total, 8 207 
unique strain types were identified. The largest cluster contained 14 isolates, with the 208 
next two clusters containing 4 and 2 isolates. The second and third cluster were 209 
unrelated to the first cluster and to each other. Four unique isolates, unrelated to any 210 
other isolates in the study, were also identified.  211 
 Two isolates, both prospective MRSA isolates, were mupirocin resistant, by both 212 
phenotypic and genotypic (mupA) methods. None of the isolates tested contained the 213 
chlorhexidine tolerance gene, qacA/B.  214 
 215 
Retrospective evaluation of the potential impact of Xpert MRSA/SA on 216 
Antimicrobial Stewardship. For 27 subjects in the study, MRSA was recovered in 217 
culture from a clinical specimen that was not evaluated as part of the study-- tracheal 218 
aspirate (24 from 15 subjects), bronchoalveolar lavage (8 from 7 subjects), blood (8 219 
from 5 subjects), bronchial washing (6 from 6 subjects), sputum (1), joint fluid (1), 220 
abscess (1) and wound (1), with a subset of patients (n = 6) having more than one 221 
positive culture.  Nares screening swabs for MRSA active surveillance were positive for 222 
9 subjects.    223 
Of the 100 subjects associated with the prospective specimen set, 96 received 224 
vancomycin and/or linezolid. The four subjects who did not receive these agents were 225 
negative for MRSA based on both Xpert MRSA/SA and culture.    226 
Vancomycin was administered to 88 patients for a total of 748 total antibiotic 227 
days, and a mean duration of 8.5 days. Linezolid was administered to 28 patients for a 228 
total of 305 total antibiotic days and a mean duration of 10.9 days. If the anti-MRSA 229 
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agent had been discontinued 1 calendar day after a negative MRSA PCR result in 230 
patients without any additional culture or PCR results positive for MRSA (including 231 
surveillance swabs), total antibiotic days and mean duration would have decreased. 232 
Vancomycin total antibiotic days would have decreased by 68.4% (512 days) to a mean 233 
duration of 2.7 days; and linezolid would have decreased by 83% (253 days) to a mean 234 
duration of 1.9 days. 235 
 236 
Cost analysis. An approximate cost estimate for a single Xpert MRSA/SA assay is $60; 237 
thus for 100 patients, the test costs would have been $6,000. This is an underestimate 238 
of true cost as it does not account for quality control testing, repeat testing, equipment 239 
acquisition, or labor.  Based on the John’s Hopkins Antibiotic Guide, average wholesale 240 
prices for the evaluated antimicrobials are estimated to be approximately $15.56 per 241 
day (based on a dose of 1 g b.i.d.) for vancomycin and $240.22 per day (based on a 242 
dose of 600 mg b.i.d.) for linezolid [10]. This is also an underestimate as it does not take 243 
into account drug administration costs or expenses for therapeutic drug monitoring and 244 
other laboratory testing, such as laboratory testing to monitor renal function in patients 245 
receiving vancomycin therapy. It also does not take into account the costs associated 246 
with complications due to these antibiotics, particularly vancomycin and renal injury. If 247 
vancomycin usage was reduced by 512 days, it would result in savings of $7,966.72 in 248 
drug cost, and if linezolid usage was decreased by 253 days, it would result in savings 249 
of $60,775.66 in drug cost. Based on these estimates, the total potential antibiotic 250 
savings were $62,742.38. Thus, an estimate of potential cost savings would be $627.42 251 
per patient.   252 
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 253 
Discussion 254 
Antimicrobial resistance is an increasing threat in the U.S. and worldwide. The 255 
CDC has recently listed MRSA as one of the current antibiotic threats in the U.S. and 256 
has assigned it a threat level of “Serious” [11]. One core approach to address 257 
antimicrobial resistance is to reduce unnecessary antibiotic use, and in order to do so, it 258 
is imperative to reduce the window of diagnostic uncertainty, thus shortening the 259 
duration of empiric antibiotics. 260 
The Infectious Diseases Society of America (IDSA) recently published a public 261 
policy document declaring that in order for tests to have a positive impact on patient 262 
care, new tests need to provide information about the causative organism, including 263 
antimicrobial susceptibility/resistance information, if possible, and must have rapid 264 
results, ideally within 1 hour [12,13]. Even with the development of rapid assays, 265 
however, the positive impact on patient care can only be achieved if physicians act 266 
quickly upon the results and start adequate or stop inadequate antibiotics. Such tests 267 
have been scrutinized for the detection of bloodborne pathogens, in a number of 268 
studies, often with a positive impact in antimicrobial stewardship efforts [14-16]. There 269 
are currently no commercial pathogen-specific assays available for evaluating 270 
respiratory specimens for hospital-acquired pneumonia (HAP) or VAP, although the 271 
MRSA/SA SSTI assay has been evaluated off-label in this and two prior studies. 272 
One specimen that was positive for MRSA by routine culture was negative by the 273 
MRSA/SA SSTI assay. A limitation of the Xpert assay compared to culture is that the 274 
assay may not detect emerging SCCmec variants, and it is possible that the isolate may 275 
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have been an SCCmec variant [17]. Laboratories considering implementing the assay 276 
should consider local epidemiology before relying on PCR to exclude the presence of S. 277 
aureus in respiratory tract specimens. 278 
Seven specimens (2 MRSA, 5 MSSA) were positive by the MRSA/SA SSTI 279 
assay but negative by culture. All 7 specimens had spa PCR cycle thresholds greater 280 
than 30 when tested by the MRSA/SA SSTI assay, suggesting that the organism burden 281 
in these specimens was low.   Alternatively, the PCR assay may have been detecting 282 
remnant DNA from dead organisms. Three additional MRSA PCR positive specimens 283 
also had spa cycle thresholds greater than 30, but those 3 were recovered in culture. 284 
However, in those 3 cases, MRSA was not recovered in routine culture and was only 285 
recovered when a larger volume (500 µl) was evaluated. The organism burden in these 286 
specimens may thus represent colonization rather than infection, or it may represent 287 
non-viable organisms after exposure to antimicrobials, such as linezolid or vancomycin.  288 
Laboratories considering such testing may wish to modify the Ct cutoff value for 289 
reporting positive PCR results from respiratory specimens.    290 
Two previous studies have examined the performance of the MRSA/SA SSTI 291 
assay on LRT specimens. In a validation study, the sensitivity, specificity, and positive 292 
and negative predictive values were 99%, 72.2%, 90.7% and 96.3%, respectively, when 293 
compared with quantitative cultures for detecting MRSA in LRT samples [3]. Leone et 294 
al. utilized the assay to evaluate the presence of MSSA or MRSA in LRT samples of 295 
patients with suspected VAP, and reported negative predictive values of 99.7% and 296 
99.8%, respectively. In contrast to the evaluation described herein (where MRSA 297 
prevalence was 8%), a limitation of the Leone study is that the reported MRSA 298 
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prevalence was <2%. Neither study estimated the impact of the assay on antimicrobial 299 
stewardship efforts or antimicrobial cost avoidance. Other studies have evaluated 300 
automated microscopy of mini-bronchoalveolar lavage specimens [18], nares MRSA 301 
screening [19] and the Gram stain of a respiratory specimen [20] for the likelihood and 302 
diagnosis of VAP. 303 
 The strengths of this study include that it was conducted in a high-prevalence, 304 
high-acuity setting and that it included a calculation of total antibiotic days, potential 305 
antibiotic days saved, and an estimated cost savings analysis. In addition, the strain 306 
typing and characterization data demonstrate that multiple S. aureus strain types were 307 
recovered from the patients in this study. The variety of strain types detected verifies 308 
that off-label use of the assay is capable of detecting multiple S. aureus strain types, 309 
and it also proves that the study, although conducted at a single center, did not simply 310 
repeatedly test the same clone.  311 
The limitations of this study include the fact that the assay results were not 312 
reported for use into routine clinical care, and all the clinical data were obtained 313 
retrospectively from the medical record. Thus, the cost analysis presented is an 314 
estimate based on the assumption that the assay results would have impacted 315 
antimicrobial therapy. In addition, the cost analysis does not take into consideration 316 
patients without clinical improvement after 48-72 h, where discontinuation of 317 
vancomycin or linezolid would be unlikely to occur. However, these data suggest that 318 
incorporation of this test into the management of ICU patients suspected to have VAP 319 
has the potential to provide cost savings to hospitals.  320 
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There are currently no commercially available assays for rapid detection of 321 
MRSA/MSSA in LRT specimens, and thus, off-label use of the Xpert MRSA/SA SSTI 322 
assay is a promising alternative for the microbiological diagnosis of VAP. Herein, we 323 
demonstrate the sensitivity and specificity of this approach, and suggest that rapid 324 
detection of MRSA in LRT specimens using this assay could be a tool to support 325 
antimicrobial stewardship efforts in patients with suspected ventilator-associated 326 
pneumonia.  Prospective studies incorporating this approach into routine clinical use are 327 
needed to confirm these findings.     328 
 329 
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Table 1. Detection of MRSA and MSSA in Prospective Samples (n=100) 420 
 MRSA Culture Positive Culture Negative 
Xpert Positive 5 5 
Xpert Negative 1 89 
 
 MSSA Culture Positive Culture Negative 
Xpert Positive 3 7 
Xpert Negative 0 90 
23 
 
Table 2.  Xpert MRSA/SA Results for Positive Prospective Lower Respriatory Tract Specimens  421 
 422 
 423 
 424 
 425 
 426 
 427 
 428 
 429 
 430 
 431 
 432 
 433 
 434 
 435 
 436 
 437 
Abbreviations: BAL, bronchoalveolar lavage; BW, bronchial washing; TA, tracheal aspirate; Ct, cycle threshold 438 
*N/A indicates an isolate was not recovered, so testing was not performed. None indicates the absence of a detectable SCCmec type.  439 
Specimen Type 
(BAL, BW or TA) 
Culture 
Result 
Xpert MRSA/SA 
Result 
spa Ct 
Value 
mecA Ct 
Value 
scc Ct 
Value 
SCCmec 
Type* 
mupA 
(PCR/disk 
diffusion 
testing) 
TA Positive MSSA   24.2 29.8 0 None Negative/S 
BAL Negative MSSA  35.3 0 0 N/A N/A 
BAL Positive MRSA 30.3 30.3 31.6 II Negative/S 
TA Positive MSSA  26.2 33.3 0 None Negative/S 
BAL Negative MSSA  30.6 0 0 N/A N/A 
BAL Negative MRSA   32.4 31.1 33.4 N/A N/A 
BAL Positive MRSA 20.3 21.0 22.1 II Negative/S 
TA Positive MSSA 16.5 21.6 0 None Negative/S 
TA Positive MSSA 29.9 0 0 None Negative/S 
BAL Positive MRSA 32.6 28.4 29.1 II Negative/S 
BAL Positive MSSA 27.0 0 0 None Negative/S 
BAL Negative MRSA 32.5 32.9 34.6 N/A N/A 
TA Positive MRSA 21.1 21.2 22.5 II Positive/R 
BAL Negative MSSA 34.6 0 0 N/A N/A 
TA Positive MRSA 17.6 17.8 19.2 IV Negative/S 
BAL Positive MRSA 27.0 27.3 28.4 II Positive/R 
BAL Negative MSSA 35.5 0 0 N/A N/A 
BAL Positive MRSA 23.1 23.3 24.5 IV Negative/S 
BAL Negative MSSA 33.4 0 0 N/A N/A 
BW Positive MRSA 31.4 31.8 33.1 II Negative/S 
